

Bevacizumab-awwb

Printed from <https://www.cancerquest.org/node/6464> on 02/24/2026

Brand name: Mvasi

FDA approval: Yes

[Enlace del fabricante](#)

Usage:

Mvasi is given by IV infusion and the treatment is given over 90 minutes for the first infusion. Dosage depends on the person's size and type of cancer being treated. How often you receive the medication is varied from patient to patient, as well as the other medication taken during treatment.

Mechanism:

Bevacizumab-awwb is a biosimilar monoclonal antibody that binds to and inhibits the activity of vascular endothelial growth factor (VEGF). This prevents the VEGF from interacting with its receptor on endothelial cells (lining of blood vessel). This, in turn, inhibits the formation of new blood vessels, which slows down the growth of the particular tissue. In essence, it kills tumors by cutting off their blood supply. [1](#)

¹ <https://www.oncolink.org/cancer-treatment/chemotherapy/oncolink-rx/bevacizumab-awwb-mvasi>

Side effects:

Common side effects of Mvasi include: epistaxis, headache, hypertension, rhinitis, proteinuria, taste alteration, dry skin, hemorrhage, lacrimation disorder, and exfoliative dermatitis.

Serious expected side effects of Mvasi include: perforation or fistula, arterial and venous thromboembolic events, hypertension, posterior reversible encephalopathy syndrome, proteinuria, infusion-relation reactions, and ovarian failure. [1](#)

¹ <https://www.oncolink.org/cancer-treatment/chemotherapy/oncolink-rx/bevacizumab-awwb-mvasi>